Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5435_Библиотеки_им_академика_М_И_Перельмана
.pdf
focus on various molecular targets and strategies. Identification or selection of promi-
nent molecular targets in the fight toward drug resistance is urged for developing ef-
fective treatments. Drug-resistant molecular targets are specific components within
cells or organisms that can mutate or adapt in a way that reduces the effectiveness of
drugs [2, 3]. In this contrast, there are some key strategies like studying drug efflux
pumps, genetic mutations in target, and resistance mechanisms specific to the patho-
gen or disease of intere st. Advanced tech nologies like genomics and proteomics can
aid in this research. It’s a complex and evolving field with ongoing discoveries [2–4].
Prominent molecular targets against drug resistance can vary depending on the
specific disease or pathogen, but some common ones include:
1) Drug efflux pumps: Identifying and targeting efflux pumps that expel drugs
from cells, r educing their effectiveness. Bacterial and cancer cells often develop
efflux pumps that expel drugs from the cell. Inhibiting these pumps can enhance
the effectiveness of drugs [5].
2) Genetic mutations in target proteins: Identifying and targeting specific genetic
mutations that confer resistance is crucial. For instance, in cancer, drugs like ty-
rosine kinase inhibitors target specific mutated proteins. To continuously monitor
the genetic changes in pathogens to detect emerging resistance and adapt treat-
ment strategies accordingly, epigenetic changes can play a role in drug resistance.
Drugs targeting epigenetic modifications, such as DNA methylation or histone
modifications, can be effective. Understanding mutations in tar get proteins that
render drugs less effective and developing drugs can still bind to these mutated
proteins [6, 7].
3) Cell signaling pathways: Disrupting signaling pathways that promote drug resis-
tance can sensitize cells to treatment. This approach is commonly used in cancer
therapy [8].
4) Alternative metabolic pathways: Some resistant cells switch to alternative met-
abolic pathways. Targeting these pathways can make cells more susceptible to
treatment [9].
5) Immune system modulation: Developing immunotherapies that boost the host’s
immune response to overcome drug-resistant pathogens. Enhancing the immune
response against cancer cells or pathogens can help overcome resistance. Immu-
notherapies, like checkpoint inhibitors, are best-fit examples [10].
6) Biofilm disruption: For bacterial infections, disrupting biofilms can make bacte-
ria more susceptible to antibiotics [11].
7) Plasm ids: Targeting plasmids carrying resistance genes in bacteria to prevent
their spread [12].
8) Quorum sensing inhibitors: Interfering with quorum sensing mechanisms in
bacteria to disrupt communication and reduce resistance [13].
9) Host-pathog en interactions: Understanding how pathogens evade the host im-
mune system and developing therapies to counteract these mechanisms [14].
404 Bhupender Nehra et al.
https://t.me/med1917
10) Antibiotic adjuvants: Developing compounds that can enhance the effectiveness
of existing antibiotics [15].
11) Combination therapies: Using multiple drugs that target different aspects of re-
sistance simultaneously can be more effective than single-drug treatments [16].
12) Nanotechnology: Nanosized drug delivery systems can improve drug penetra-
tion and reduce resistance by delivering drugs directly to the target site [17].
13) CRISPR-Cas9 technology: Genetic editing techniques like CRISPR-Cas9 can poten-
tially reverse drug resistance by correcting genetic mutations [18].
14) Patient-specific approaches: Tailoring treatments to an individual’s genetic pro-
file and drug response can be highly effective in overcoming resistance [19].
The choice of molecular targets depends on the specific context of drug resistance,
and a multidisciplinary approach involving genomics, proteomics, and bioinformatics
is often necessary for effective identification and targeting. It’s essential to adapt strat-
egies to the specific context of drug resistance as it can vary widely between diseases
and even between individual patients [20]. Ongoing research in these areas continues
to advance our understanding and treatment options for drug resistance.
16.2 Major mechanisms for combating
drug resistance
Drug resistance is one of the various strategies employed by microorganisms as shown
in Figure 16.1, such as bacteria, viruses, and cancer cells, to evade or reduce the effec-
tiveness of drugs that were originally designed to target and eliminate them. These
mechanisms can be complex and multifaceted. Understanding these drug resistance
mechanisms is vital for developing strategies to overcome resistance such as the devel-
Figure 16.1: Process of developing antimicrobial resistance.
16 Identifying prominent molecular targets in the fight against drug resistance 405
https://t.me/med1917
opment of new drugs, combination therapies, and improved diagnostic techniques to
guide treatment decisions [21]. Additionally, responsible antibiotic and antiviral use can
help mitigate the development of drug resistance in microbial populations. There are
some major mechanisms for combating drug resistance. They vary depending on the
specific disease or condition [21, 22]. Some common strategies for addressing resistance
in different contexts are mentioned below.
16.2.1 Mechanisms for combating drug resistance
in bacterial infections
– Bacterial cell wall synthesis: Targeting enzymes involved in cell wall synthesis,
like penicillin-binding proteins (PBPs), can overcome antibiotic resistance.
– Efflux pumps: Inhibit ing efflux pumps that expe l antibiotics from bacterial cells
can enhance drug efficacy.
– Ribosomal machinery: Targeting bacterial ribosomes or translation factors can
disrupt protein synthesis, making bacteria more susceptible to antibiotics [23].
16.2.2 Mechanisms for combating drug resistance in cancer
There are various anticancer agents available in market that works by acting on spe-
cific phase of cell cycle or through target-based mechanisms, whereas resistance has
been acquired by cancerous cells against particular class of anticancer drugs (as
shown in Figure 16.2) for tackling the anticancer potential. Moreover, major mecha-
nisms to avoid anticancer drug resistance are given below:
– Oncogenic mutations: Targeting specific mutated proteins or pathways driving
cancer growth, such as EGFR or BRAF mutations, can overcome resistance.
– Angiogenesis: Inhibiting angiogenesis by targeting vascular endothelial growth
factor (VEGF) can reduce the blood supply to tumors.
– DNA repair mechanisms: Inhibiting DNA repair proteins can sensitize cancer
cells to DNA-damaging treatments like chemotherapy and radiation therapy.
– Immune checkpoints: Blocking immune checkpoint proteins like PD-1 and CTLA-4
can enhance the immune system’s ability to target cancer cells [24, 25].
406 Bhupender Nehra et al.
https://t.me/med1917
16.2.3 Mechanisms for combating drug resistance
in viral infections
– Viral proteins: Targeting essential viral proteins, such as reverse transcriptase or
protease, can prevent viral replication.
– Entry inhibition: Blocking viral entry into host cells by targeting viral envelope
proteins or host cell receptors can prevent infection [26].
16.2.4 Mechanisms for combating drug resistance
in parasitic diseases
– Drug transporters: Inhibiting drug transporters in parasitic organisms can in-
crease drug retention and effectiveness.
Figure 16.2: Resistance mechanisms adopted by cancer cells against specific class of anticancer drugs.
16 Identifying prominent molecular targets in the fight against drug resistance 407
https://t.me/med1917
– Metabolic pathways: Targeting specific metabolic pathways unique to parasites,
like the heme synthesis pathway in Plasmodium species, can be effective [27].
16.2.5 Mechanisms for combating drug resistance
in fungal infections
– Ergosterol biosynthesis: Disrupting ergosterol synthesis, a key component of fun-
gal cell membranes, is a common target.
– Cell wall synthesis: Inhibiting enzymes involvedinfungalcellwallsynthesis,
such as beta-glucan synthase, can combat resistance [28].
16.2.6 Mechanisms for combating antibiotic-resistant tuberculosis
– Mycobacterial cell wall: Targeting components of the mycobacterial cell wall, like
mycolic acids or enzymes involved in their synthesis, can be effective.
These are just a few examples of mechanisms involved for resistance in various dis-
eases. Research in this field is ongoing, and the development of new therapies often
involves a combination of these strategies and personalized approaches to combat
drug resistance effectively. However, this is a general overview about mechanisms re-
quired to be addressed to develop effective treatment against drug resistance [29].
16.3 Molecular targets to fight against
drug resistance
“Molecular targets” in the context of drug development and pharmacology refer to spe-
cific molecules or structures within an organism, often at the cellular or molecular level,
that a drug is designed to interact with or affect. These molecular targets are typically
proteins, but they can also include nucleic acids (like DNA or RNA) or other cellular com-
ponents [30]. The interaction between a drug and its molecular target is what determines
the drug’s therapeutic effect. Scientific community is mainly focused on molecular targets
that are associated with the resistance against available drug regimen. Nowadays, re-
searchers totally concentrate over structural variations of resistant molecular target fol-
lowed by the development of potent drug molecules to combat the same. They aim to
design drugs that selectively interact with their intended targets while minimizing off-
target effects, which can lead to side effects[31,32].Thisknowledgealsoallowsforthe
development of personalized medicine approaches, where treatments are tailored to an
individual’s specific molecular profile or disease characteristics. In this context, there are
408 Bhupender Nehra et al.
https://t.me/med1917
many reported molecular targets that are used to combat the resistance against available
drugs, and these molecular targets are widely exploited by researchers to develop more
promising and least toxic drug substances. Molecular targets to combat drug resistance
vary depending on the specific disease or condition [33, 34]. Here are some common mo-
leculartargetsandexamplesofdiseasesorcontextswheretheycanbetargeted.
16.3.1 Molecular targets to fight against antibacterial
drug resistance
Antibacterial drugs, also known as antibiotics, are medications used to treat bacterial
infections. These drugs work by targeting and either killing the bacteria or inhibiting
their growth. There are several mechanisms associated with potential of antibacterial
agents as mentioned in Figure 16.3. Antibiotics are a crucial component of modern
medicine, as they have saved countless lives by effectively treating bacterial infec-
tions. It’s important to note that antibiotics are effective against bacterial infections
but are not effective against viral infections. Overuse and misuse of antibiotics can
lead to antibiotic resistance, where bacteria become less responsive to the drugs. To
combat antibiotic resistance, it is essential to use antibiotics judiciously and only
when they are medically necessary [34–36].
Antibacterial drug-resistant targets are specific components within bacteria that can
undergo genetic mutations or changes to reduce the effectiveness of antibacterial
drugs. Here are some examples of antibacterial drug-resistant targets:
Figure 16.3: Various mechanisms associated with antibacterial agents.
16 Identifying prominent molecular targets in the fight against drug resistance 409
https://t.me/med1917
– PBPs are a group of bacterial proteins involved in cell wall synthesis and mainte-
nance. They play a crucial role in the bacterial cell envelope, which consists of
the cell membrane and the peptidoglycan cell wall. PBPs are called “pe nicillin-
binding” proteins because they are the target of antibiotics like penicillin and
other beta-lactam antibiotics. PBPs are targeted in antibiotic-resistant bacteria.
Bacteria can alter these proteins, which are the target of beta-lactam antibiotics
like penicillin, making the drugs less effective [37].
– Efflux pumps are generally targeted to prevent drug expulsion from bacterial
cells. Transport proteins in bacterial cell membranes pump drugs out of the cell.
Overexpression or mutations in efflux pump genes can reduce intracellular drug
concentrations, leading to resistance [38].
– Extended-spectrum beta-lactamases (ESBLs): These are enzymes produced by bac-
teria to resist beta-lactam antibiotics. Enzymes produced by bacteria that hydro-
lyze a broad range of beta-lactam antibiotics. ESBL production is a common
mechanism of resistance against penicillin’s and cephalosporins [39].
– MRSA (methicillin-resistant Staphylococcus aureus): A type of bacteria resistant to
many antibiotics including methicillin. MRSA produces a modified penicillin-
binding protein (PBP2a) that is less susceptible to beta-lactam antibiotics [40].
– DNA gyrase and topoisomerase IV: Mutations in these enzymes like GyrA and
ParC lead to resistance against fluoroquinolone antibiotics. Quinolone resistance-
determining region is a region within DNA gyrase and top oisomerase IV genes
that can acquire mutations, reducing susceptibility to quinolone antibiotics.
These enzymatic mutations resulted in resistance by reducing drug binding and
inhibitory effects [41].
– Ribosomal RNA (rRNA): It is generally targeted by drugs like macrolides and tetra-
cyclines. Mutations in the ribosomal RNA genes can result in resistance by reduc-
ing drug binding to the ribosome [42].
– Folate pathway enzymes: Resistance can occur through mutations in genes encod-
ing these enzymes, reducing the effectiveness of folate synthesis inhibition. Dihy-
drofolate reductase (DHFR) resistance can develop through mutations in the
DHFR gene, reducing drug binding and inhibition (mainly targeted by sulfona-
mides and trimethoprim) [43].
– Beta-lactamases: Enzymes are produced by bacteria that break down beta-lactam
antibiotics. Resistance can result from the production of beta-lactamases that in-
activate the drugs [44].
These examples illustrate the diversity of antibacterial drug-resistant targets and the
mechanisms by which resistance can develop. Understanding these targets is crucial
for developing new antibiotics and strategies to combat drug-resistant bacteria.
410 Bhupender Nehra et al.
https://t.me/med1917
16.3.2 Molecular targets to fight against anticancer
drug resistance
Anticancer drugs, also known as cancer chemotherapyorcancermedications,aremedica-
tions specifically designed to treat cancer. These drugs work by targeting and inhibiting the
growthandspreadofabnormallyproliferated cells. Anticancer drugs can be used alone or
in combination with other cancer treatments like surgery, radiation therapy, or immuno-
therapy, depending on the type and stage of cancer. The choice of treatment depends on
factors such as the type and stage of cancer, the patient’s overall health, and the presence of
specific genetic mutations [45, 46]. Treatmentregimensareoftentailored to individual pa-
tients through personalized medicine approaches to optimize effectiveness and minimize
side effects. Anticancer drug resistance is a significant challenge in the field of oncology, as
it can limit the effectiveness of cancer treatments and lead to disease progression. Cancer
cells can develop various mechanisms of resistance to survive against chemotherapy drugs,
targeted therapies, and other anticancer treatments as discussed in Figure 16.4. Combating
anticancer drug resistance is an ongoing challenge, and researchers continue to explore
novel targets and combination therapies to overcomeresistancemechanismsinvariouscan-
cer types. Individualized treatment approaches based on a patient’s specific tumor profile
are also being investigated to optimize therapeutic outcomes. To combat resistance to anti-
cancer drugs, researchers target specific molecular mechanisms and pathways [46, 47]. Here
are some key molecular targets and strategies used to address anticancer drug resistance:
– EGFR (epidermal growth factor receptor): EGFR-targeted therapies like erlotinib
and gefitinib are used to inhibit EGFR activity in certain cancers, especially used
in lung cancer. Resistance mechanism carries T790M mutation in the EGFR gene.
– BCR-ABL T315I mutation: A mutation in the BCR-ABL gene is linked to resistance
to tyrosine kinase inhibitors in leukemia.
– ALK (anaplastic lymphoma kinase): ALK inhibitory agents like crizotinib and cer-
itinib target ALK in ALK-positive lung cancer. Resistance mechanism exhibits sec-
ondary mutations in the ALK gene.
– HER2 (human epidermal growth factor receptor 2): HER2 inhibitors like trastuzumab
and lapatinib target HER2 in HER2-positive breast and gastric cancer. Resistance
mechanism explores the hyperactivation of downstream signaling pathways [48, 49].
– BRAF (V-Raf murine sarcoma viral oncogene homolog B): BRAF inhibitors such as
vemurafenib and dabrafenib target mutated BRAF in melanoma and certain
other cancers. Resistance mechanism involves the acquisition of secondary muta-
tions in BRAF or activation of alternative pathways.
– p53 (tumor suppressor gene): p53 reactivation: The research focuses on restoring
p53 function in cancers with p53 mutations. The resistance mech anism involves
the loss or mutation of p53 gene.
– PD-1 (programmed cell death protein 1) and CTLA-4 (cytotoxic T-lymphocyte-
associated protein 4): Immune checkpoint inhibitors like pembrolizumab and ipi-
limumab target these molecules to enhance the immune response against cancer.
16 Identifying prominent molecular targets in the fight against drug resistance 411
https://t.me/med1917
Resistance mechanisms can involve upregulation of alternative immune check-
points or immune evasion strategies [50, 51].
– VEGF): VEGF inhibitors like bevacizumab target angiogenesis in cancers. Resis-
tance mechanisms can involve upregulation of alternative angiogenic pathways.
– Heat shock protein 90 (HSP90): Target HSP90 to destabilize client proteins includ-
ing oncogenic kinases. Resistance mechanisms involve the upr egulation of com-
pensatory pathways.
Figure 16.4: Survival or relapse process of cancerous cells.
412 Bhupender Nehra et al.
https://t.me/med1917
– mTOR (mammalian target of rapamycin): Drugs like everolimus inhibit mTOR signaling
in some cancers. Resistance can involve activation of alternative signaling pathways.
– DNA repair pathways: Targeting DNA repair enzymes such as PARP (poly-ADP-
ribose polymerase) in DNA repair-deficient cancers. Resistance mechanisms may
involve restoration of DNA repair capabilities. PARP inhibitors such as olaparib
and niraparib target PARP in BRCA-mutated ovarian and breast cancers. In the
resistant conditions, mechanism involves restoration of homologous recombina-
tion repair [46, 50–52].
In the above discussion, almost all molecular targets are mentioned that may be mu-
tated to resist the effect of anticancer drugs on cancerous cell. Moreover, Figure 16.5
mentions all possible mechanisms that can be attempted by cancer cells to overcome
the inhibitory potential of anticancer agents.
Figure 16.5: Various mechanisms associated with anticancer drugs resistance.
16 Identifying prominent molecular targets in the fight against drug resistance 413
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана